mefruside

Mefruside is a sulfonamide diuretic primarily used for the treatment of hypertension and edema. It acts by reducing the reabsorption of electrolytes, particularly sodium and chloride ions, from the renal tubules, leading to increased excretion of these ions along with water. This results in a diuretic effect that helps manage fluid retention and lower blood pressure[1][3][4]. Mefruside also reduces glomerular filtration rate and may have a weak direct vasodilating action in addition to its indirect effects on blood pressure[6]. Its onset of action is typically 2–4 hours after oral administration, with a prolonged duration making it suitable for maintenance therapy[1][8]. Developed in Germany in the late 1960s by Bayer, mefruside has structural similarities to frusemide (furosemide) and thiazides but offers an enhanced sodium/potassium excretion ratio[5].

Brand names

Baycaron